Ardelyx provided an update on January 13, 2025, announcing preliminary unaudited total U.S. net product sales revenue of approximately $319 million for the full year 2024. This reflects sustained growth for both IBSRELA and XPHOZAH.
IBSRELA's net product sales revenue for 2024 is expected to be approximately $158 million, including about $54 million in the fourth quarter. For 2025, Ardelyx anticipates IBSRELA net sales revenue to be between $240.0 million and $250.0 million, reaffirming its peak annual sales expectation of greater than $1 billion.
XPHOZAH achieved approximately $161 million in net product sales revenue in its first full year of commercialization, with about $57 million in the fourth quarter of 2024. The company reaffirmed its peak annual net sales expectation for XPHOZAH at $750 million. Ardelyx ended 2024 with approximately $250 million in cash, cash equivalents, and investments.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.